Cargando…
Factors associated with prolonged duration of viral clearance in non-severe SARS-CoV-2 patients in Osaka, Japan
BACKGROUND: We investigated factors associated with prolonged viral clearance of SARS-CoV-2 among non-severe adult patients in Osaka, Japan. A total of 706 laboratory-confirmed COVID-19 patients were enrolled in this longitudinal observational study between 29 January 2020 and 31 May 2020, across 62...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8647504/ https://www.ncbi.nlm.nih.gov/pubmed/34872493 http://dx.doi.org/10.1186/s12199-021-01035-y |
_version_ | 1784610618065551360 |
---|---|
author | Hoffman, Emma Nakagawa Kawachi, Haruna Hirayama, Atsushi Zhang, Jingwen Murayama, Ayumi Masui, Jun Fujita, Satomi Mori, Yasushi Hirayama, Takanori Ohara, Toshitake Asada, Rumiko Iso, Hiroyasu |
author_facet | Hoffman, Emma Nakagawa Kawachi, Haruna Hirayama, Atsushi Zhang, Jingwen Murayama, Ayumi Masui, Jun Fujita, Satomi Mori, Yasushi Hirayama, Takanori Ohara, Toshitake Asada, Rumiko Iso, Hiroyasu |
author_sort | Hoffman, Emma Nakagawa |
collection | PubMed |
description | BACKGROUND: We investigated factors associated with prolonged viral clearance of SARS-CoV-2 among non-severe adult patients in Osaka, Japan. A total of 706 laboratory-confirmed COVID-19 patients were enrolled in this longitudinal observational study between 29 January 2020 and 31 May 2020, across 62 hospitals and three non-hospital recuperation facilities. METHODS: Logistic regression analysis was performed to investigate the factors associated with prolonged (29 days: upper 25% in duration) viral clearance of SARS-CoV-2. Linear regression analysis was conducted to assess these factors 14 days after symptom onset. RESULTS: The median duration of viral clearance was 22 days from symptom onset. After adjustment for sex, age, symptoms, comorbidity, and location of recuperation, comorbidities were associated with prolonged duration: (OR, 1.77 [95% CI, 1.11–2.82]) for one, (OR, 2.47 [95% CI, 1.32–4.61]) for two or more comorbidities. Viral clearance 14 days after symptom onset was 3 days longer for one comorbidity and 4 days longer for two or more comorbidities compared to clearance when there was no comorbidity. CONCLUSION: The presence of comorbidity was a robust factor associated with a longer duration of viral clearance, extending by 3 to 4 days compared to patients with no comorbidity. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12199-021-01035-y. |
format | Online Article Text |
id | pubmed-8647504 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-86475042021-12-06 Factors associated with prolonged duration of viral clearance in non-severe SARS-CoV-2 patients in Osaka, Japan Hoffman, Emma Nakagawa Kawachi, Haruna Hirayama, Atsushi Zhang, Jingwen Murayama, Ayumi Masui, Jun Fujita, Satomi Mori, Yasushi Hirayama, Takanori Ohara, Toshitake Asada, Rumiko Iso, Hiroyasu Environ Health Prev Med Research Article BACKGROUND: We investigated factors associated with prolonged viral clearance of SARS-CoV-2 among non-severe adult patients in Osaka, Japan. A total of 706 laboratory-confirmed COVID-19 patients were enrolled in this longitudinal observational study between 29 January 2020 and 31 May 2020, across 62 hospitals and three non-hospital recuperation facilities. METHODS: Logistic regression analysis was performed to investigate the factors associated with prolonged (29 days: upper 25% in duration) viral clearance of SARS-CoV-2. Linear regression analysis was conducted to assess these factors 14 days after symptom onset. RESULTS: The median duration of viral clearance was 22 days from symptom onset. After adjustment for sex, age, symptoms, comorbidity, and location of recuperation, comorbidities were associated with prolonged duration: (OR, 1.77 [95% CI, 1.11–2.82]) for one, (OR, 2.47 [95% CI, 1.32–4.61]) for two or more comorbidities. Viral clearance 14 days after symptom onset was 3 days longer for one comorbidity and 4 days longer for two or more comorbidities compared to clearance when there was no comorbidity. CONCLUSION: The presence of comorbidity was a robust factor associated with a longer duration of viral clearance, extending by 3 to 4 days compared to patients with no comorbidity. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12199-021-01035-y. BioMed Central 2021-12-06 2021 /pmc/articles/PMC8647504/ /pubmed/34872493 http://dx.doi.org/10.1186/s12199-021-01035-y Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Hoffman, Emma Nakagawa Kawachi, Haruna Hirayama, Atsushi Zhang, Jingwen Murayama, Ayumi Masui, Jun Fujita, Satomi Mori, Yasushi Hirayama, Takanori Ohara, Toshitake Asada, Rumiko Iso, Hiroyasu Factors associated with prolonged duration of viral clearance in non-severe SARS-CoV-2 patients in Osaka, Japan |
title | Factors associated with prolonged duration of viral clearance in non-severe SARS-CoV-2 patients in Osaka, Japan |
title_full | Factors associated with prolonged duration of viral clearance in non-severe SARS-CoV-2 patients in Osaka, Japan |
title_fullStr | Factors associated with prolonged duration of viral clearance in non-severe SARS-CoV-2 patients in Osaka, Japan |
title_full_unstemmed | Factors associated with prolonged duration of viral clearance in non-severe SARS-CoV-2 patients in Osaka, Japan |
title_short | Factors associated with prolonged duration of viral clearance in non-severe SARS-CoV-2 patients in Osaka, Japan |
title_sort | factors associated with prolonged duration of viral clearance in non-severe sars-cov-2 patients in osaka, japan |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8647504/ https://www.ncbi.nlm.nih.gov/pubmed/34872493 http://dx.doi.org/10.1186/s12199-021-01035-y |
work_keys_str_mv | AT hoffmanemmanakagawa factorsassociatedwithprolongeddurationofviralclearanceinnonseveresarscov2patientsinosakajapan AT kawachiharuna factorsassociatedwithprolongeddurationofviralclearanceinnonseveresarscov2patientsinosakajapan AT hirayamaatsushi factorsassociatedwithprolongeddurationofviralclearanceinnonseveresarscov2patientsinosakajapan AT zhangjingwen factorsassociatedwithprolongeddurationofviralclearanceinnonseveresarscov2patientsinosakajapan AT murayamaayumi factorsassociatedwithprolongeddurationofviralclearanceinnonseveresarscov2patientsinosakajapan AT masuijun factorsassociatedwithprolongeddurationofviralclearanceinnonseveresarscov2patientsinosakajapan AT fujitasatomi factorsassociatedwithprolongeddurationofviralclearanceinnonseveresarscov2patientsinosakajapan AT moriyasushi factorsassociatedwithprolongeddurationofviralclearanceinnonseveresarscov2patientsinosakajapan AT hirayamatakanori factorsassociatedwithprolongeddurationofviralclearanceinnonseveresarscov2patientsinosakajapan AT oharatoshitake factorsassociatedwithprolongeddurationofviralclearanceinnonseveresarscov2patientsinosakajapan AT asadarumiko factorsassociatedwithprolongeddurationofviralclearanceinnonseveresarscov2patientsinosakajapan AT isohiroyasu factorsassociatedwithprolongeddurationofviralclearanceinnonseveresarscov2patientsinosakajapan |